RNA定序市場:第3版

定序市場繼續提供強大的工具，預計在不久的將來徹底改變醫療保健領域。過去十年，產品推出、新應用以及最終用戶實驗室爭相進入這些新領域都出現了爆炸性增長。近年來，隨著 RNA 定序的出現取代並超越，用於 RNA 表現分析的微陣列的使用已顯著下降。與金標準定量逆轉錄 PCR (q-RT-PCR) 類似，需要預定義探針是微陣列的主要弱點之一，而 RNA-seq 提供了許多優勢。

本報告提供全球RNA定序市場相關調查，市場概要，以及趨勢，課題，策略，企業，關於產品論述，提供著市場佔有率和收益成長的估計。

目錄

第1章 摘要整理

第2章 市場趨勢

• 簡介
• 趨勢
• 臨床診斷，臨床調查的應用
• 癌症- 白血病/血液疾病，固態腫瘤
• 感染疾病
• 稀少遺傳性疾病/遺傳性疾病
• COVID-19
• Illumina的多元化產品
• 其他公司的NGS產品·技術
• CDC的SPHERES聯盟
• 新產品的持續性引進
• 單一細胞RNA序列
• 嚴選的產品·技術
• 軟體/生物資訊學
• 在許多領域的夥伴關係，收購，交易

第3章 市場分析

• 市場分析
• 市場佔有率

第4章 企業簡介

• 企業簡介
  • 10X Genomics
  • Agilent Technologies
  • Illumina
  • New England Biolabs
  • Oxford Nanopore Technologies
  • Pacific Biosciences (PacBio)
  • Standard BioTools
  • Takara Bio Inc.
  • Tecan
  • Thermo Fisher Scientific

The sequencing market has continued to provide powerful tools that hold the promise of bringing major changes to healthcare in the near future. In the last decade, explosive growth has occurred in terms of product introductions, new applications, and the end-user labs rushing to participate in these new areas. In recent years, the use of microarrays for RNA expression analysis has dropped greatly as RNA sequencing has risen to replace and outshine it. Similar to quantitative reverse transcription-PCR (q-RT-PCR) which has been the gold standard, there is a need for pre-defined probes which creates one of the major weaknesses of microarrays, and RNA-seq provides a number of advantages including:

• improved sensitivity and dynamic range
• ability to study species without reference
• measurement of focal changes (such as single nucleotide variants, insertions and deletions)
• detection of different transcript isoforms, splice variants and chimeric gene fusions (including previously unidentified genes and/or transcripts)

This report, “The Market for RNA Sequencing, 3^rd Edition”, focuses on the market for RNA sequencing products - the hardware, service of the hardware, software, and consumables including for the sequencing step itself. It discusses trends, challenges, strategies, companies, and products, and provides estimates of market share and revenue growth for the market.

Information in this report includes:

• RNA Sequencing Market, 2022 and 2027
• RNA Sequencing Consumables Market, 2022 and 2027
• RNA Sequencing Equipment-Related Services Market, 2022 and 2027
• RNA Sequencing Software Market, 2022 and 2027
• RNA Sequencing Vendor Share
• Products on The Market
• Software Products
• Innovations
• Clinical Sequencing and Products on the Market

The competitive situation and deals are covered in respective chapters. The report was produced through a combination of primary research, secondary research, and internal databases, including SEC filings, product literature, corporate websites, conferences, journals, and trade publications.

Companies Profiled Include:

TABLE OF CONTENTS

CHAPTER 1: EXECUTIVE SUMMARY

• Table 1-1: RNA Sequencing Revenues by Product Segment (Consumables, Systems/Hardware, Service, and Software), 2022 (in millions of $)
• Figure 1-1: RNA Sequencing Revenues by Product Segment (Consumables, Systems/Hardware, Service, and Software), 2022 (percent)
• Scope and Methodology
• Report Structure

CHAPTER 2: MARKET TRENDS

• Introduction
• Trends
• Clinical Diagnostics, Clinical Research Applications
• Cancer - leukemia/ hematological diseases; solid tumors
• Infectious diseases
• Rare inherited/ genetic diseases
  • Table 2-1: Selected RNA-Seq Diagnostic/ Clinical Products and Technologies
• COVID-19
• Illumina's Diverse Range of Products
• Other Companies' NGS Products and Technologies
• CDC's SPHERES Consortium
• Ongoing Introductions of New Products
  • Table 2-2: RNA-Sequencing Product Introductions, October 2018- July 2023
• Single-cell RNA Sequencing
• Selected Products/ Technologies
  • Table 2-3: Selected RNA-Seq Products and Technologies
• Software/Bioinformatics
  • Table 2-4: Selected RNA-Seq Software and Related IT Tools
• Partnerships, Acquisitions, Deals in Many Areas
  • Table 2-5: RNA-Seq Collaborations, Acquisitions and Other Deals, October 2014-August 2023

CHAPTER 3: MARKET ANALYSIS

• Market Analysis
  • Table 3-1: RNA Sequencing Revenues, by Market Segment (Consumables, Systems/Hardware, Service, and Software), 2022-2027 (in millions of dollars)
  • Figure 3-1: RNA Sequencing Revenues, by Market Segment (Consumables, Systems/Hardware, Service, and Software), 2022-2027 (in millions of dollars)
  • Table 3-2: RNA Sequencing Revenue Shares, by Market Segment (Consumables, Systems/Hardware, Service, and Software), 2022-2027 (percent)
  • Figure 3-2: RNA Sequencing Revenue Shares, by Market Segment (Consumables, Systems/Hardware, Service, and Software), 2022 (percent)
  • Figure 3-3: RNA Sequencing Revenue Shares, by Market Segment (Consumables, Systems/Hardware, Service, and Software), 2027 (percent)
• Market Shares
  • Table 3-3: RNA Sequencing Market Revenue Share, by Leading Companies (Illumina, Thermo, and Other), 2022 (millions of dollars and percent)
  • Figure 3-4: RNA Sequencing Revenue Shares, by Market Segment (Consumables, Systems/Hardware, Service, and Software), 2022 (percent)
  • Table 3-4: RNA Sequencing Market Revenue Share, by Region (North America, Europe, APAC, and Rest of World), 2021 (millions of dollars and percent)
  • Figure 3-5: RNA Sequencing Market Revenue Share, by Region (North America, Europe, APAC, and Rest of World), 2021 (percent)

CHAPTER 4: COMPANY PROFILES

• Company Profiles
  • 10X Genomics
  • Agilent Technologies
  • Illumina
  • New England Biolabs
  • Oxford Nanopore Technologies
  • Pacific Biosciences (PacBio)
  • Standard BioTools
  • Takara Bio Inc.
  • Tecan
  • Thermo Fisher Scientific